Business Context and Reporting Period
Company: pSivida Corp. (Note: Input metadata referenced "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: pSivida develops miniaturized, injectable drug delivery systems. Key assets include Iluvien (Phase III for diabetic macular edema, licensed to Alimera), Retisert and Vitrasert (FDA-approved, licensed to Bausch & Lomb), and BioSilicon/BrachySil (cancer treatment candidate). The company relies heavily on collaboration agreements with Alimera Sciences and Pfizer for funding and development.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2009 | Nine Months Ended Mar 31, 2009 | Balance Sheet (Mar 31, 2009) |
|---|---|---|---|
| Total Revenues | $3.16 million | $8.94 million | - |
| Net Loss | $(0.64) million | $(1.98) million | - |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.11) | - |
| Operating Expenses | $3.94 million | $13.52 million | - |
| Cash and Cash Equivalents | - | - | $8.02 million |
| Total Assets | - | - | $36.37 million |
| Total Liabilities | - | - | $15.28 million |
| Stockholders' Equity | - | - | $21.09 million |
| Accumulated Deficit | - | - | $(226.51) million |
Cash Flow (Nine Months Ended Mar 31, 2009):
- Net cash used in operating activities: $(7.30) million
- Net cash used in investing activities: $(0.17) million
- Net cash provided by financing activities: $0 (No financing activity in current period; prior year had $18.4 million)
Material Changes vs. Prior Period
- Revenue Surge: Revenues increased 484% ($2.62 million) for the quarter and 1,056% ($8.17 million) for the nine months compared to the prior year. This is primarily due to the recognition of deferred revenue from the amended collaboration agreement with Alimera Sciences signed in March 2008.
- Expense Reduction: Operating expenses decreased significantly. R&D expenses dropped 48% (quarterly) and 49% (nine-month) largely because Alimera assumed financial responsibility for Iluvien development. G&A expenses decreased 42% (quarterly) and 15% (nine-month) due to reduced legal/audit fees following U.S. reincorporation and office closures.
- Improved Net Loss: Net loss narrowed from $(5.50) million to $(0.64) million for the quarter, and from $(12.09) million to $(1.98) million for the nine months, driven by higher revenue recognition and lower operating costs.
- Derivative Income: Income from the change in fair value of derivatives decreased significantly ($1.15 million drop for the quarter) compared to the prior year, though it still contributed $22,000 (quarter) and $1.58 million (nine months) to income.
- One-Time Charge: The nine-month period included a $1.3 million provision for losses on a note receivable from GEM Global Yield Fund, recorded in G&A expenses.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes cash of $8.0 million is sufficient to fund operations through at least December 31, 2010. This assumption relies on continued quarterly funding from Pfizer ($500,000/quarter), Alimera funding for Iluvien, and the resumption of Retisert royalties from Bausch & Lomb before June 30, 2010.
- Future Cash Position: Beyond December 2010, liquidity depends heavily on the FDA approval and commercialization of Iluvien. Alimera has agreed to pay a $25.0 million milestone upon FDA approval.
- Retisert Royalties: The company does not expect to record Retisert royalty income through at least the quarter ending December 31, 2009, as Bausch & Lomb retains royalties to recoup an advance payment.
- Key Risks:
- Failure to achieve regulatory approval for Iluvien or BrachySil.
- Termination or modification of key collaboration agreements with Alimera and Pfizer.
- Inability to raise additional capital if needed.
- Material weakness in internal controls over financial reporting regarding foreign currency translation (identified in prior year, currently being remediated).
Investor Verification Checklist
- Collaboration Continuity: Verify the status of funding commitments from Alimera and Pfizer, as these are critical to the company's liquidity runway through 2010.
- Retisert Royalty Resumption: Monitor sales data for Retisert to determine when Bausch & Lomb will have recouped the advance royalty, triggering payments to pSivida.
- Internal Controls: Review the progress of remediation efforts for the material weakness in internal controls related to foreign currency translation.
- Derivative Liability Sensitivity: Note that the $352,000 derivative liability is sensitive to share price fluctuations; a 10% increase in share price could increase the liability by approximately $84,000.
- Intangible Asset Amortization: Confirm the remaining useful life (8.75 years) and amortization schedule for the $26.8 million in intangible assets, which impacts future operating expenses.